Generation Bio Co.(GBIO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2025-09-30.

Generation Bio Co. (GBIO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GBIO at 23.1/100 on a 32-signal composite quality model, placing it at rank #2,631 of 2,856 stocks — the bottom half of the AI-ranked universe. GBIO scores in the top quartile across revenue growth (93.4). Areas of concern include institutional flow (1.3) and free cash flow (2.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q3 2025), Generation Bio Co. reports quarterly revenue of $1.6M, net income of $-5.5M, free cash flow of $-52.7M. GBIO trades on the Nasdaq exchange and files with the SEC under CIK 1733294. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GBIO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Generation Bio Co. directly from SEC EDGAR.